ARS Pharmaceuticals (SPRY) stock price is $4.29, up 1.42% on the day, as of Oct 20, 2026. It has a market cap of $423.57Mn, and is classified in the Pharmaceuticals industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap423.57 Mn
P/E-1.97
P/S3.62
Div. Yield0.00
Total Debt (Qtr)74.93 Mn
Revenue Growth (1y) (Qtr)114.15
Add ratio to table…
About
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy a needle free intranasal epinephrine spray for the emergency treatment of type I allergic reactions including anaphylaxis. The product uses a proprietary formulation of epinephrine combined with the absorption enhancer Intravail to enable low dose nasal delivery that matches the exposure of injectable epinephrine. neffy 2 mg is approved for adults and children…
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy a needle free intranasal epinephrine spray for the emergency treatment of type I allergic reactions including anaphylaxis. The product uses a proprietary formulation of epinephrine combined with the absorption enhancer Intravail to enable low dose nasal delivery that matches the exposure of injectable epinephrine. neffy 2 mg is approved for adults and children weighing 30 kg or more while neffy 1 mg is approved for children aged 4 years and older who weigh between 15 kg and 30 kg. The therapy has received regulatory approval in the United States the European Union the United Kingdom Japan Australia and China and is under review by Health Canada with a decision expected in 2026. It represents the first approved needle free epinephrine therapy in more than three decades.
Revenue is generated primarily from the sale of neffy to wholesalers and pharmacies as well as from milestone payments and royalties under collaboration agreements with partners such as Alfresa Pediatrix Seqirus and ALK. The company also receives upfront payments and sales based milestones from these agreements which contribute to its overall income. In the United States ARS Pharmaceuticals maintains a direct sales force of 106 representatives targeting high volume prescribers and a co promotion team of approximately 70 representatives working with ALK US to reach pediatricians. The firm supports its sales effort with a direct to consumer marketing campaign that includes streaming television broadcast and cable advertising as well as digital channels and disease awareness initiatives. Additionally the company operates a virtual prescriber platform getneffy.com that allows patients to obtain a prescription online and has launched disease education programs with advocacy groups.
The company operates in a market dominated by epinephrine auto injectors such as EpiPen from Viatris and its generic equivalents from Teva as well as Adrenaclick Auvi Q and Symjepi. ARS Pharmaceuticals differentiates itself with its needle free delivery system which eliminates needle related pain and improves ease of use and portability. Being the first approved nasal spray epinephrine product gives the company a first mover advantage and a protected intellectual property portfolio extending to 2038. Clinical studies show that neffy delivers comparable pharmacodynamic responses to injectable epinephrine with similar reductions in systolic blood pressure and heart rate during allergic reactions. Real world data from the neffy experience program indicated that approximately 90% of patients treated with a single dose during anaphylaxis event achieved symptom control matching the efficacy of traditional injection. The product also avoids needle associated risks such as accidental injection into blood vessels lacerations or caregiver self injury which are reported with auto injector use.
The company serves patients who experience severe allergic reactions and their caregivers as well as healthcare providers including allergists pediatricians and primary care physicians who prescribe the product. Distribution occurs through pharmaceutical wholesalers and retail pharmacies that stock the medication for patient access. As of February 2026 more than 22,500 physicians had prescribed neffy since its launch indicating a growing base of clinical adopters. The firm reports that approximately 93% of commercial insurance plans provide some level of coverage for neffy while 57% offer coverage without prior authorization and eight of 50 state Medicaid programs cover the drug without prior authorization. These coverage statistics help drive patient access and support the commercial rollout in the United States.
Sector:HealthcareSector rationaleARS Pharmaceuticals is a biopharmaceutical company that develops and commercializes neffy, a needle-free intranasal epinephrine spray for treating anaphylaxis. Its revenue is generated from the sale of this medical product to wholesalers and pharmacies, as well as through pharmaceutical collaboration agreements involving milestones and royalties.Industry:PharmaceuticalsPharmaceuticalsPrimaryARS Pharmaceuticals develops and markets neffy, a branded prescription intranasal epinephrine spray for the emergency treatment of anaphylaxis. Revenue is generated from the sale of this branded pharmaceutical product to wholesalers and pharmacies.Classified using BQ-MICSCIK: 0001671858
Bull & bear
Investment Thesis
▲ Bull case
SPRY is positioned to capture meaningful market share growth in the U.S. epinephrine market due to the imminent resolution of its CVS Caremark formulary approval process, which targets a July 1 effective date for removing prior authorization requirements across Caremark, Aetna, and Anthem plans covering approximately 24% of commercial lives. Management expressed high conviction in this outcome based on ongoing negotiations, noting that aligning neffy with other epinephrine auto-injectors on formulary status will eliminate a key barrier to prescribing. This development, combined with the new retail pharmacy cash price program capping patient out-of-pocket costs at $199 for rejected commercial claims, directly addresses the historical friction point where patients faced costs exceeding $1,000 at retail, thereby reducing prescription abandonment and increasing HCP willingness to prescribe. The timing is especially advantageous as the company enters its second back-to-school season—a period responsible for a disproportionate share of annual epinephrine prescriptions—and has already expanded its sales force to 148 representatives focused on high-volume prescribing practices that drive roughly 50% of market volume. Early signs of refill behavior are emerging, with families beginning to renew prescriptions ahead of the school year to avoid mid-term expiration, a trend that should scale as the installed base matures and contributes to more predictable, recurring revenue streams. Furthermore, neffy’s recent regulatory wins—including Health Canada’s approval as the first needle-free emergency treatment for allergic reactions and the European Commission’s marketing authorization for Euro neffy 1mg—validate its differentiated profile and open international pathways that management noted are being actively pursued by partner ALK, with potential to diversify revenue beyond the U.S. market. These factors collectively suggest that SPRY is transitioning from a new entrant reliant on in-office prescriptions to a scalable player benefiting from refill-driven dynamics, improved access, and affordability initiatives that could drive revenue acceleration in the second half of 2026 and into 2027, potentially exceeding current consensus estimates if CVS Caremark approval is secured and refill adoption gains traction.
SPRY is positioned to capture meaningful market share growth in the U.S. epinephrine market due to the imminent resolution of its CVS Caremark formulary approval process, which targets a July 1 effective date for removing prior authorization requirements across Caremark, Aetna, and Anthem plans covering approximately 24% of commercial lives. Management expressed high conviction in this outcome based on ongoing negotiations, noting that aligning neffy with other epinephrine auto-injectors on formulary status will eliminate a key barrier to prescribing. This development, combined with the new retail pharmacy cash price program capping patient out-of-pocket costs at $199 for rejected commercial claims, directly addresses the historical friction point where patients faced costs exceeding $1,000 at retail, thereby reducing prescription abandonment and increasing HCP willingness to prescribe. The timing is especially advantageous as the company enters its second back-to-school season—a period responsible for a disproportionate share of annual epinephrine prescriptions—and has already expanded its sales force to 148 representatives focused on high-volume prescribing practices that drive roughly 50% of market volume. Early signs of refill behavior are emerging, with families beginning to renew prescriptions ahead of the school year to avoid mid-term expiration, a trend that should scale as the installed base matures and contributes to more predictable, recurring revenue streams. Furthermore, neffy’s recent regulatory wins—including Health Canada’s approval as the first needle-free emergency treatment for allergic reactions and the European Commission’s marketing authorization for Euro neffy 1mg—validate its differentiated profile and open international pathways that management noted are being actively pursued by partner ALK, with potential to diversify revenue beyond the U.S. market. These factors collectively suggest that SPRY is transitioning from a new entrant reliant on in-office prescriptions to a scalable player benefiting from refill-driven dynamics, improved access, and affordability initiatives that could drive revenue acceleration in the second half of 2026 and into 2027, potentially exceeding current consensus estimates if CVS Caremark approval is secured and refill adoption gains traction.
SPRY faces significant near-term execution risks that could undermine its growth trajectory, particularly its continued reliance on new patient acquisition rather than refill behavior, which remains the dominant driver in the mature epinephrine market where approximately half of all prescriptions are renewals written electronically without office visits. Despite management’s optimism about refill contributions beginning this summer, the company acknowledged that neffy has largely depended on in-office prescriptions to date, and there is no clear evidence yet of a meaningful shift toward electronic refill adoption—a critical hurdle given that prescribers often default to established products in automated workflows. The expansion of the sales force to 148 representatives, while framed as a strategic move to target high-volume practices, increases SG&A expenses in an already high-cost structure, with Q1 SG&A reaching $72.2 million against $22.7 million in revenue, implying a sales and marketing intensity that may not be sustainable without faster-than-expected revenue conversion. Furthermore, the anticipated benefit from the CVS Caremark formulary change remains contingent on final approval, which management noted has been delayed due to PBM focus on new legislation and FTC-related interactions, introducing uncertainty around the July 1 effective date and the potential for a watered-down outcome that fails to fully remove prior authorization barriers. Internationally, while Health Canada and EU approvals are positive, neffy’s commercial launch in Canada is dependent on partner ALK, which is still in early stages of rollout across multiple countries, and the royalty payments from this relationship were negligible in Q1—less than $100,000—suggesting that near-term international revenue will remain immaterial and not offset U.S. commercialization costs. Finally, the company’s path to cash breakeven by mid-2027 relies on assumptions of declining losses through the second half of 2026, yet Q1 reflected a historically weak quarter for epinephrine due to deductible resets, and there is no guarantee that improved access will translate into proportional prescription volume, especially if payer policies shift or if consumer awareness campaigns fail to convert awareness into sustained prescribing behavior among lower-decile physicians who represent a large portion of the market but lower volume per prescriber.
SPRY faces significant near-term execution risks that could undermine its growth trajectory, particularly its continued reliance on new patient acquisition rather than refill behavior, which remains the dominant driver in the mature epinephrine market where approximately half of all prescriptions are renewals written electronically without office visits. Despite management’s optimism about refill contributions beginning this summer, the company acknowledged that neffy has largely depended on in-office prescriptions to date, and there is no clear evidence yet of a meaningful shift toward electronic refill adoption—a critical hurdle given that prescribers often default to established products in automated workflows. The expansion of the sales force to 148 representatives, while framed as a strategic move to target high-volume practices, increases SG&A expenses in an already high-cost structure, with Q1 SG&A reaching $72.2 million against $22.7 million in revenue, implying a sales and marketing intensity that may not be sustainable without faster-than-expected revenue conversion. Furthermore, the anticipated benefit from the CVS Caremark formulary change remains contingent on final approval, which management noted has been delayed due to PBM focus on new legislation and FTC-related interactions, introducing uncertainty around the July 1 effective date and the potential for a watered-down outcome that fails to fully remove prior authorization barriers. Internationally, while Health Canada and EU approvals are positive, neffy’s commercial launch in Canada is dependent on partner ALK, which is still in early stages of rollout across multiple countries, and the royalty payments from this relationship were negligible in Q1—less than $100,000—suggesting that near-term international revenue will remain immaterial and not offset U.S. commercialization costs. Finally, the company’s path to cash breakeven by mid-2027 relies on assumptions of declining losses through the second half of 2026, yet Q1 reflected a historically weak quarter for epinephrine due to deductible resets, and there is no guarantee that improved access will translate into proportional prescription volume, especially if payer policies shift or if consumer awareness campaigns fail to convert awareness into sustained prescribing behavior among lower-decile physicians who represent a large portion of the market but lower volume per prescriber.